 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2194 News |  |
| «12...2223242526272829303132...3334» |
- | Climara (estradiol) / Bausch Health, Bayer
Trial completion, Enrollment change, Trial primary completion date: Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women (clinicaltrials.gov) - Nov 29, 2017
P=N/A, N=25, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Completed | N=34 --> 25 | Trial primary completion date: Dec 2018 --> Sep 2017
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Nov 14, 2017
P3, N=3775, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=34 --> 25 | Trial primary completion date: Dec 2018 --> Sep 2017 Initiation date: Jul 2015 --> Jul 2016
- | Trial primary completion date: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Nov 13, 2017
P3, N=249, Completed, Sponsor: Fudan University
Initiation date: Jul 2015 --> Jul 2016 Trial primary completion date: Oct 2017 --> Feb 2017
- | Trial completion, Trial primary completion date: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Oct 31, 2017
P3, N=249, Completed, Sponsor: Fudan University
Trial primary completion date: Oct 2017 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017
- | Enrollment closed, Trial primary completion date: Regulation of Cervical Mucus Secretion (clinicaltrials.gov) - Oct 27, 2017
P4, N=10, Active, not recruiting, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Aug 2017
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty (clinicaltrials.gov) - Oct 20, 2017
P4, N=68, Recruiting, Sponsor: Jin Soon Hwang
- | Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
Enrollment change: Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=36, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Aug 2017 N=30 --> 36
- | Erleada (apalutamide) / J&J
New P2 trial: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (clinicaltrials.gov) - Oct 17, 2017
P2, N=42, Not yet recruiting, Sponsor: Tian Zhang, MD
- | Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial suspension, Trial primary completion date, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Oct 16, 2017
P2, N=42, Suspended, Sponsor: Lawrence Fong
N=30 --> 36 Recruiting --> Suspended | Trial primary completion date: Apr 2019 --> Apr 2020
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Enrollment closed, Surgery: RADICALS-HD: RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery (clinicaltrials.gov) - Oct 13, 2017
P3, N=4236, Active, not recruiting, Sponsor: Medical Research Council
Recruiting --> Suspended | Trial primary completion date: Apr 2019 --> Apr 2020 Recruiting --> Active, not recruiting
- ||||||| leuprolide acetate for depot suspension / Generic mfg., zoledronic acid / Generic mfg.
Trial completion: TROG 03.04 - RADAR: RADAR Trial - Randomised Androgen Deprivation and Radiotherapy (clinicaltrials.gov) - Oct 12, 2017
P3, N=1071, Completed, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control (clinicaltrials.gov) - Oct 5, 2017
P1, N=5, Completed, Sponsor: Parc de Salut Mar
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erleada (apalutamide) / J&J
New P2 trial: SOLAR: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer (clinicaltrials.gov) - Sep 28, 2017
P2, N=28, Not yet recruiting, Sponsor: VA Office of Research and Development
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Sep 20, 2017
P2, N=259, Recruiting, Sponsor: Palleos Healthcare GmbH
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Kisqali (ribociclib) / Novartis
Enrollment change, Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Sep 15, 2017
P3, N=3775, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=3000 --> 3775 | Initiation date: May 2016 --> Jul 2015
- || sunitinib / Generic mfg.
Trial primary completion date: Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) - Sep 13, 2017
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=3000 --> 3775 | Initiation date: May 2016 --> Jul 2015 Trial primary completion date: Dec 2018 --> May 2019
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Sep 4, 2017
P2, N=259, Not yet recruiting, Sponsor: Palleos Healthcare GmbH
- ||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Aug 23, 2017
P3, N=3000, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2018 --> May 2019 Initiation date: Nov 2016 --> May 2016
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 18, 2017
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Nov 2016 --> May 2016 Trial primary completion date: Jul 2017 --> Jul 2018
- ||| Erleada (apalutamide) / J&J
Trial initiation date, Trial primary completion date: Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer (clinicaltrials.gov) - Aug 3, 2017
P2, N=66, Not yet recruiting, Sponsor: Robert J Amato
Trial primary completion date: Jul 2017 --> Jul 2018 Initiation date: Jul 2017 --> Dec 2017 | Trial primary completion date: Jul 2021 --> Dec 2021
- | Erleada (apalutamide) / J&J
Enrollment open: A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 3, 2017
P2, N=33, Recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Jul 2017 --> Dec 2017 | Trial primary completion date: Jul 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- | tamoxifen / Generic mfg.
Phase classification: ASPAIT: Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (clinicaltrials.gov) - Aug 2, 2017
P3, N=680, Recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Not yet recruiting --> Recruiting Phase classification: P2 --> P3
- Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Jul 26, 2017
P1, N=25, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Phase classification: P2 --> P3 Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Jul 25, 2017
P2, N=56, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2017 --> Oct 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Females, Aging, Metabolism, and Exercise (clinicaltrials.gov) - Jul 18, 2017
P=N/A, N=132, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Jul 17, 2017
P2, N=19, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015
- | leuprolide acetate for depot suspension / Generic mfg.
Biomarker, Enrollment open: Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov) - Jul 16, 2017
P4, N=58, Recruiting, Sponsor: Brigham and Women's Hospital
N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) - Jul 14, 2017
P=N/A, N=72, Recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- orteronel (TAK 700) / Takeda
New P2 trial, Surgery: NEPTUNE: A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone (clinicaltrials.gov) - Jul 7, 2017
P2, N=16, Terminated, Sponsor: Centre of Experimental Medicine
- ||| leuprolide acetate for depot suspension / Generic mfg.
New trial: Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer" (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=300, Active, not recruiting, Sponsor: Takeda
- ||| leuprolide acetate for depot suspension / Generic mfg.
New trial: Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer" (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=300, Recruiting, Sponsor: Takeda
- ||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Jul 2, 2017
P=N/A, N=300, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Jun 20, 2017
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2016 --> Mar 2018
- | Erleada (apalutamide) / J&J
Trial initiation date: A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jun 20, 2017
P2, N=33, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Mar 2016 --> Mar 2018 Initiation date: Apr 2017 --> Jun 2017
- |||| Piqray (alpelisib) / Novartis
Enrollment open, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Jun 20, 2017
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Apr 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment open, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jun 8, 2017
P2, N=42, Recruiting, Sponsor: Lawrence Fong
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Jun 5, 2017
P3, N=288, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| stapuldencel-T (DCVAC/PCa) / Sotio
Trial completion, Combination therapy, Metastases: ASN-002-IL: Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer (clinicaltrials.gov) - May 24, 2017
P2, N=63, Completed, Sponsor: Sotio a.s.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Orgalutran (ganirelix acetate) / Organon
Phase classification: Follicle-Stimulating Hormone (FSH) and the Onset of Puberty (clinicaltrials.gov) - May 22, 2017
P, N=11, Completed, Sponsor: University of Utah
Active, not recruiting --> Completed Phase classification: P=N/A --> P
- || Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - May 19, 2017
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P=N/A --> P Trial primary completion date: Dec 2017 --> Dec 2018
- | orteronel (TAK 700) / Takeda
Enrollment change: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - May 19, 2017
P3, N=239, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Dec 2017 --> Dec 2018 N=900 --> 239
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - May 18, 2017
P1, N=26, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
N=900 --> 239 Recruiting --> Active, not recruiting | N=50 --> 26
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Metastases: A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer (clinicaltrials.gov) - May 4, 2017
P2, N=60, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting | N=50 --> 26 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment change, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Apr 25, 2017
P2, N=42, Not yet recruiting, Sponsor: Lawrence Fong
Recruiting --> Active, not recruiting N=60 --> 42
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Apr 21, 2017
P2, N=160, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
N=60 --> 42 Trial primary completion date: Mar 2020 --> Dec 2019
- ||| Erleada (apalutamide) / J&J
Trial initiation date, Trial primary completion date: Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer (clinicaltrials.gov) - Apr 19, 2017
P2, N=66, Not yet recruiting, Sponsor: Robert J Amato
Trial primary completion date: Mar 2020 --> Dec 2019 Initiation date: Nov 2016 --> Jul 2017 | Trial primary completion date: Nov 2020 --> Jul 2021
- ||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Trial primary completion date: A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants (clinicaltrials.gov) - Apr 13, 2017
P4, N=300, Active, not recruiting, Sponsor: Takeda
Initiation date: Nov 2016 --> Jul 2017 | Trial primary completion date: Nov 2020 --> Jul 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Dec 2018
- | Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Apr 12, 2017
P2, N=30, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Dec 2018 Active, not recruiting --> Completed | N=48 --> 30 | Trial primary completion date: Jun 2018 --> Apr 2017
- |||| Firmagon (degarelix) / Astellas, Ferring
Trial primary completion date, Adverse events, Metastases: PRONOUNCE: A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (clinicaltrials.gov) - Apr 12, 2017
P3, N=900, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed | N=48 --> 30 | Trial primary completion date: Jun 2018 --> Apr 2017 Trial primary completion date: Oct 2019 --> Dec 2020
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Apr 4, 2017
P2, N=92, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Oct 2019 --> Dec 2020 Trial primary completion date: Mar 2017 --> Dec 2018